GB201206486D0 - Vesicular formulations and uses thereof - Google Patents

Vesicular formulations and uses thereof

Info

Publication number
GB201206486D0
GB201206486D0 GBGB1206486.1A GB201206486A GB201206486D0 GB 201206486 D0 GB201206486 D0 GB 201206486D0 GB 201206486 A GB201206486 A GB 201206486A GB 201206486 D0 GB201206486 D0 GB 201206486D0
Authority
GB
United Kingdom
Prior art keywords
vesicular
pain
relates
vesicular formulations
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1206486.1A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sequessome Technology Holdings Ltd
Original Assignee
Sequessome Technology Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sequessome Technology Holdings Ltd filed Critical Sequessome Technology Holdings Ltd
Priority to GBGB1206486.1A priority Critical patent/GB201206486D0/en
Publication of GB201206486D0 publication Critical patent/GB201206486D0/en
Priority to SI201331990T priority patent/SI2836203T1/sl
Priority to IN8259DEN2014 priority patent/IN2014DN08259A/en
Priority to EP13715989.3A priority patent/EP2836203B1/en
Priority to BR112014025507-5A priority patent/BR112014025507B1/pt
Priority to GB1419074.8A priority patent/GB2515439B/en
Priority to DK13715989.3T priority patent/DK2836203T3/da
Priority to LTEPPCT/EP2013/057742T priority patent/LT2836203T/lt
Priority to ES13715989T priority patent/ES2916803T3/es
Priority to HUE13715989A priority patent/HUE058972T2/hu
Priority to MX2014012198A priority patent/MX2014012198A/es
Priority to HRP20220700TT priority patent/HRP20220700T1/hr
Priority to PT137159893T priority patent/PT2836203T/pt
Priority to CA2870111A priority patent/CA2870111A1/en
Priority to PL13715989T priority patent/PL2836203T3/pl
Priority to US14/391,754 priority patent/US20150065461A1/en
Priority to JP2015504977A priority patent/JP2015512926A/ja
Priority to KR1020147031478A priority patent/KR102204725B1/ko
Priority to CN201380031159.3A priority patent/CN104363894B/zh
Priority to EA201491583A priority patent/EA039626B1/ru
Priority to AU2013246822A priority patent/AU2013246822A1/en
Priority to PCT/EP2013/057742 priority patent/WO2013153221A1/en
Priority to SG11201406251VA priority patent/SG11201406251VA/en
Priority to PH12014502079A priority patent/PH12014502079A1/en
Priority to IL234862A priority patent/IL234862A0/en
Priority to CL2014002706A priority patent/CL2014002706A1/es
Priority to CO14249925A priority patent/CO7141430A2/es
Priority to US15/349,792 priority patent/US20170128473A1/en
Priority to US17/142,624 priority patent/US20210393655A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GBGB1206486.1A 2012-04-12 2012-04-12 Vesicular formulations and uses thereof Ceased GB201206486D0 (en)

Priority Applications (29)

Application Number Priority Date Filing Date Title
GBGB1206486.1A GB201206486D0 (en) 2012-04-12 2012-04-12 Vesicular formulations and uses thereof
SG11201406251VA SG11201406251VA (en) 2012-04-12 2013-04-12 Vesicular formulations for use in the treatment of pain or reduced mobility of a joint
PL13715989T PL2836203T3 (pl) 2012-04-12 2013-04-12 Formulacje pęcherzykowe do zastosowania w leczeniu bólu lub ograniczonej ruchomości stawu
US14/391,754 US20150065461A1 (en) 2012-04-12 2013-04-12 Vesicular Formulations for Use in the Treatment of Pain or Reduced Mobility of a Joint
EP13715989.3A EP2836203B1 (en) 2012-04-12 2013-04-12 Vesicular formulations for use in the treatment of pain or reduced mobility of a joint
BR112014025507-5A BR112014025507B1 (pt) 2012-04-12 2013-04-12 Uso de uma formulação vesicular
GB1419074.8A GB2515439B (en) 2012-04-12 2013-04-12 Vesicular formulations for use in the treatment of reduced mobility
DK13715989.3T DK2836203T3 (da) 2012-04-12 2013-04-12 Vesikulær formulering til anvendelse til behandling af smerter eller nedsat mobilitet i et led
LTEPPCT/EP2013/057742T LT2836203T (lt) 2012-04-12 2013-04-12 Vezikulių vaisto formos, skirtos naudoti sąnario skausmo arba sumažėjusio judrumo gydymui
ES13715989T ES2916803T3 (es) 2012-04-12 2013-04-12 Formulaciones vesiculares para su uso en el tratamiento del dolor o de la movilidad reducida de una articulación
HUE13715989A HUE058972T2 (hu) 2012-04-12 2013-04-12 Vezikuláris készítmények az ízületi fájdalmának vagy csökkent mobilitásának kezelésében történõ alkalmazásra
MX2014012198A MX2014012198A (es) 2012-04-12 2013-04-12 Formulaciones vesiculares para su uso en el tratamiento del dolor o movilidad reducida de una articulacion.
HRP20220700TT HRP20220700T1 (hr) 2012-04-12 2013-04-12 Vezikularne formulacije za uporabu u liječenju boli ili smanjene pokretljivosti zgloba
PT137159893T PT2836203T (pt) 2012-04-12 2013-04-12 Formulações vesiculares para utilização no tratamento de dor ou de mobilidade reduzida de uma articulação
CA2870111A CA2870111A1 (en) 2012-04-12 2013-04-12 Vesicular formulations for use in the treatment of pain or reduced mobility of a joint
SI201331990T SI2836203T1 (sl) 2012-04-12 2013-04-12 Vezikularne formulacije za uporabo pri zdravljenju bolečine ali zmanjšane gibljivosti sklepa
KR1020147031478A KR102204725B1 (ko) 2012-04-12 2013-04-12 관절의 통증 및 감소된 활동성의 치료에 사용하기 위한 소포성 제형
AU2013246822A AU2013246822A1 (en) 2012-04-12 2013-04-12 Vesicular formulations for use in the treatment of pain or reduced mobility of a joint
JP2015504977A JP2015512926A (ja) 2012-04-12 2013-04-12 関節の疼痛または低減した可動性の治療用の小胞製剤
CN201380031159.3A CN104363894B (zh) 2012-04-12 2013-04-12 用于治疗关节疼痛或运动性降低的囊泡制剂
EA201491583A EA039626B1 (ru) 2012-04-12 2013-04-12 Применение везикулярной композиции для лечения сниженной подвижности сустава
IN8259DEN2014 IN2014DN08259A (enExample) 2012-04-12 2013-04-12
PCT/EP2013/057742 WO2013153221A1 (en) 2012-04-12 2013-04-12 Vesicular formulations for use in the treatment of pain or reduced mobility of a joint
PH12014502079A PH12014502079A1 (en) 2012-04-12 2014-09-22 Vesicular formulations for use in the treatment of pain or reduced mobility of a joint
IL234862A IL234862A0 (en) 2012-04-12 2014-09-28 Vascular formulations and their use for the treatment of pain or reduced mobility of a joint
CL2014002706A CL2014002706A1 (es) 2012-04-12 2014-10-08 Formulaciones vesiculares que comprenden un fosfolipido y un agente tensoactivo y el uso en el tratamiento del dolor o movilidad reducida de una articulación.
CO14249925A CO7141430A2 (es) 2012-04-12 2014-11-12 Formulaciones vesiculares para uso en el tratamiento del dolor o movilidad reducida de una articulación
US15/349,792 US20170128473A1 (en) 2012-04-12 2016-11-11 Vesicular Formulations for Use in the Treatment of Pain or Reduced Mobility of a Joint
US17/142,624 US20210393655A1 (en) 2012-04-12 2021-01-06 Vesicular Formulations for Use in the Treatment of Pain or Reduced Mobility of a Joint

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1206486.1A GB201206486D0 (en) 2012-04-12 2012-04-12 Vesicular formulations and uses thereof

Publications (1)

Publication Number Publication Date
GB201206486D0 true GB201206486D0 (en) 2012-05-30

Family

ID=46208989

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB1206486.1A Ceased GB201206486D0 (en) 2012-04-12 2012-04-12 Vesicular formulations and uses thereof
GB1419074.8A Expired - Fee Related GB2515439B (en) 2012-04-12 2013-04-12 Vesicular formulations for use in the treatment of reduced mobility

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB1419074.8A Expired - Fee Related GB2515439B (en) 2012-04-12 2013-04-12 Vesicular formulations for use in the treatment of reduced mobility

Country Status (26)

Country Link
US (3) US20150065461A1 (enExample)
EP (1) EP2836203B1 (enExample)
JP (1) JP2015512926A (enExample)
KR (1) KR102204725B1 (enExample)
CN (1) CN104363894B (enExample)
AU (1) AU2013246822A1 (enExample)
BR (1) BR112014025507B1 (enExample)
CA (1) CA2870111A1 (enExample)
CL (1) CL2014002706A1 (enExample)
CO (1) CO7141430A2 (enExample)
DK (1) DK2836203T3 (enExample)
EA (1) EA039626B1 (enExample)
ES (1) ES2916803T3 (enExample)
GB (2) GB201206486D0 (enExample)
HR (1) HRP20220700T1 (enExample)
HU (1) HUE058972T2 (enExample)
IL (1) IL234862A0 (enExample)
IN (1) IN2014DN08259A (enExample)
LT (1) LT2836203T (enExample)
MX (1) MX2014012198A (enExample)
PH (1) PH12014502079A1 (enExample)
PL (1) PL2836203T3 (enExample)
PT (1) PT2836203T (enExample)
SG (1) SG11201406251VA (enExample)
SI (1) SI2836203T1 (enExample)
WO (1) WO2013153221A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100255080A1 (en) * 2009-04-02 2010-10-07 Sesvalia Usa, Llc Liposomal ALA pharmaceutical and cosmeceutical compositions and methods of treatment
MX336482B (es) 2009-08-21 2016-01-21 Henk-Andre Kroon Formulaciones vesiculares.
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
GB201505532D0 (en) * 2015-03-31 2015-05-13 Sequessome Technology Holdings Ltd Formulations
DK3316857T3 (da) 2015-06-30 2021-10-18 Sequessome Tech Holdings Limited Multifasiske sammensætninger
HRP20230566T1 (hr) * 2017-08-22 2023-08-18 Moebius Medical Ltd. Liposomalna formulacija za podmazivanje zglobova
JP2020534285A (ja) 2017-09-15 2020-11-26 アンパサンド バイオファーマシューティカルズ インコーポレイテッドＡｍｐｅｒｓａｎｄ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 投与および処置の方法
CN110314137B (zh) * 2018-03-30 2022-04-05 北京泰德制药股份有限公司 一种含有脂质囊泡的冻干制剂
KR20230041954A (ko) 2021-09-17 2023-03-27 서울대학교산학협력단 골관절염 예방 또는 치료용 약학 조성물 및 건강기능식품

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4327193A (en) * 1992-07-08 1994-01-31 Dianorm-Gerate G. Maierhofer Liposomes, method of preparing them and their use in the preparation of drugs
AUPN723395A0 (en) * 1995-12-19 1996-01-18 Macnaught Medical Pty Limited Lubrication methods
CA2448627A1 (en) * 2001-05-31 2002-12-05 Pharmacia Corporation Skin-permeable composition comprising a selective cyclooxygenase-2 inhibitor a monohydric alcohol
JP2004535434A (ja) * 2001-06-25 2004-11-25 デピユイ 関節炎にかかった関節の処置のためのグリコサミノグリカン類のリポソームカプセル化
US7115666B2 (en) * 2002-10-15 2006-10-03 Renovis, Inc. Nitrone compounds, pharmaceutical compositions containing the same and methods for treating inflammation and neuropathic pain
CN101541308B (zh) * 2006-09-28 2012-02-01 哈达斯特医疗研究服务和开发有限公司 甘油磷脂用于关节润滑的用途
AU2010255391C1 (en) * 2009-06-03 2016-10-27 Sequessome Technology Holdings Limited Formulations for the treatment of deep tissue pain
MX336482B (es) * 2009-08-21 2016-01-21 Henk-Andre Kroon Formulaciones vesiculares.
EP2340819A1 (en) * 2009-12-23 2011-07-06 Laboratorios Del. Dr. Esteve, S.A. Compositions comprising venlafaxine and celecoxib in the treatment of pain
US9125786B2 (en) * 2011-03-31 2015-09-08 Phillip Anthony FEMANO Method and device to alleviate carpal tunnel syndrome and dysfunctions of other soft tissues
CN105229171A (zh) * 2013-03-13 2016-01-06 豪夫迈·罗氏有限公司 在人pi3kca (pik3ca)基因中检测突变的方法和组合物

Also Published As

Publication number Publication date
BR112014025507B1 (pt) 2022-01-04
ES2916803T3 (es) 2022-07-06
DK2836203T3 (da) 2022-06-07
IL234862A0 (en) 2014-12-31
CO7141430A2 (es) 2014-12-12
EP2836203B1 (en) 2022-03-09
GB2515439A (en) 2014-12-24
CN104363894A (zh) 2015-02-18
WO2013153221A1 (en) 2013-10-17
IN2014DN08259A (enExample) 2015-05-15
GB201419074D0 (en) 2014-12-10
US20210393655A1 (en) 2021-12-23
PT2836203T (pt) 2022-06-15
EP2836203A1 (en) 2015-02-18
BR112014025507A2 (pt) 2017-08-08
EA201491583A1 (ru) 2015-05-29
CL2014002706A1 (es) 2015-04-24
US20170128473A1 (en) 2017-05-11
CA2870111A1 (en) 2013-10-17
HUE058972T2 (hu) 2022-09-28
LT2836203T (lt) 2022-06-10
SI2836203T1 (sl) 2022-07-29
CN104363894B (zh) 2016-11-23
US20150065461A1 (en) 2015-03-05
AU2013246822A1 (en) 2014-10-16
KR20150008869A (ko) 2015-01-23
SG11201406251VA (en) 2014-10-30
JP2015512926A (ja) 2015-04-30
PL2836203T3 (pl) 2022-07-11
PH12014502079A1 (en) 2014-12-10
HRP20220700T1 (hr) 2022-07-08
MX2014012198A (es) 2015-06-04
EA039626B1 (ru) 2022-02-17
KR102204725B1 (ko) 2021-01-19
GB2515439B (en) 2017-08-23

Similar Documents

Publication Publication Date Title
PH12014502079A1 (en) Vesicular formulations for use in the treatment of pain or reduced mobility of a joint
NZ710111A (en) Quinoline and quinoxaline amides as modulators of sodium channels
MX2018015656A (es) Compuestos heterociclicos como antibacterianos.
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
MY188139A (en) Sodium channel modulators for the treatment of pain
NZ631144A (en) Compositions and methods for transmucosal absorption
PH12012501741A1 (en) Treatment of lupus arthritis using laquinimod
MX2016004741A (es) Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico.
MX2019008817A (es) Formulacion de liberacion prolongada para reducir la frecuencia de miccion y metodo de uso de la misma.
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
MX2015010296A (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
MX2015000398A (es) Formulaciones de laquinimod sin agente alcalinizante.
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
MX2015000485A (es) Tratamiento de esclerosis multiple con una combinacion de laquinimod y fampridina.
MX2020001428A (es) Composiciones de grapiprant y metodos para usar las mismas.
PH12014502065A1 (en) Vesicular formulations
IN2014DN09437A (enExample)
IN2014DN00123A (enExample)
WO2012044963A3 (en) Perfluorocarbons for use in treating pruritus
CO7151515A2 (es) Métodos para tratar deficiencia en la marcha y/o equilibrio en pacientes con esclerosis múltiple que utilizan una aminopiridina
MX2016001177A (es) Tratamiento de esclerosis multiple con la combinacion de laquinimod y flupirtina.
WO2014170820A3 (en) A pharmaceutical combination for treating tuberculosis
MY197404A (en) Benzoic acid or a salt and derivative thereof for use in preventing or treating depression
UA101573C2 (ru) Способ хирургического лечения больных с язвенной болезнью желудка
UA109209C2 (uk) Спосіб біоліфтингу шкіри обличчя за індріксоном

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)
S30Z Assignments for licence or security reasons

Free format text: APPLICANT. SEQUESSOME TECHNOLOGY HOLDIGS LIMITED SECURITY INTEREST. FONDS RUSNANO CAPITAL S.A.